HILBARI Trademark
Trademark Overview
On Friday, October 3, 2025, a trademark application was filed for HILBARI with the United States Patent and Trademark Office. The USPTO has given the HILBARI trademark a serial number of 99426804. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Tuesday, February 17, 2026. This trademark is owned by Celldex Therapeutics, Inc.. The HILBARI trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of mast-cell mediated disorders; Pharmaceutical preparations for the treatment of urticaria; Pharmaceutical preparations for the treatment of chronic spontaneous urticaria (CSU); Pharmaceutical preparations for the treatment of chronic inducible urticaria (CIndU); Pharmaceutical preparations for the treatment of prurigo nodularis (PN); Pharmaceutical preparations for the treatment of atopic dermatitis (AD); Pharmaceutical preparations for the treatment of cold urticaria (ColdU); Pharmaceutical preparations for the treatment of symptomatic dermographism (SD); Antibodies for medical purposes; Therapeutic antibodies for human use for the treatment of inflammatory diseases
General Information
| Serial Number | 99426804 |
| Word Mark | HILBARI |
| Filing Date | Friday, October 3, 2025 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Tuesday, February 17, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 10, 2026 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of mast-cell mediated disorders; Pharmaceutical preparations for the treatment of urticaria; Pharmaceutical preparations for the treatment of chronic spontaneous urticaria (CSU); Pharmaceutical preparations for the treatment of chronic inducible urticaria (CIndU); Pharmaceutical preparations for the treatment of prurigo nodularis (PN); Pharmaceutical preparations for the treatment of atopic dermatitis (AD); Pharmaceutical preparations for the treatment of cold urticaria (ColdU); Pharmaceutical preparations for the treatment of symptomatic dermographism (SD); Antibodies for medical purposes; Therapeutic antibodies for human use for the treatment of inflammatory diseases |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, October 3, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Celldex Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Hampton, NJ 08827
US |
Trademark Events
| Event Date | Event Description |
| Friday, October 3, 2025 | NEW APPLICATION ENTERED |
| Friday, October 3, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, October 3, 2025 | APPLICATION FILING RECEIPT MAILED |
| Friday, February 6, 2026 | ASSIGNED TO EXAMINER |
| Wednesday, February 11, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, March 4, 2026 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
